About Rocket Pharmaceuticals (NASDAQ:RCKT)
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has two lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells; and three LVV programs for the treatment of other rare genetic diseases, as well as an adeno-associated viral vector program, which is under preclinical development. The company has collaboration agreements with Lund University, Sweden; and Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas. The company is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RCKT
CUSIPN/A
Phone646-440-9100
Debt
Debt-to-Equity Ratio1.04%
Current Ratio24.83%
Quick Ratio24.83%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$7.02 per share
Price / Book2.44
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-29,490,000.00
Net MarginsN/A
Return on Equity-53.72%
Return on Assets-27.09%
Miscellaneous
Employees20
Outstanding Shares39,440,000
Rocket Pharmaceuticals (NASDAQ:RCKT) Frequently Asked Questions
What is Rocket Pharmaceuticals' stock symbol?
Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."
How were Rocket Pharmaceuticals' earnings last quarter?
Rocket Pharmaceuticals (NASDAQ:RCKT) issued its quarterly earnings data on Thursday, August, 3rd. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.47) by $0.23. View Rocket Pharmaceuticals' Earnings History.
When is Rocket Pharmaceuticals' next earnings date?
What price target have analysts set for RCKT?
4 equities research analysts have issued 1-year price targets for Rocket Pharmaceuticals' shares. Their predictions range from $2.00 to $27.00. On average, they anticipate Rocket Pharmaceuticals' share price to reach $10.6667 in the next twelve months. View Analyst Ratings for Rocket Pharmaceuticals.
Are investors shorting Rocket Pharmaceuticals?
Rocket Pharmaceuticals saw a increase in short interest in March. As of March 15th, there was short interest totalling 1,055,546 shares, an increase of 53.9% from the February 28th total of 685,907 shares. Based on an average trading volume of 361,033 shares, the short-interest ratio is presently 2.9 days. Approximately 2.9% of the shares of the stock are short sold.
Who are some of Rocket Pharmaceuticals' key competitors?
Some companies that are related to Rocket Pharmaceuticals include ImmunoGen (IMGN), Apellis Pharmaceuticals (APLS), Theravance Biopharma (TBPH), Endo International (ENDP), G1 Therapeutics (GTHX), TherapeuticsMD (TXMD), Revance Therapeutics (RVNC), Dynavax Technologies (DVAX), Mallinckrodt (MNK), PTC Therapeutics (PTCT), WAVE Life Sciences (WVE), Epizyme (EPZM), Athenex (ATNX), Intra-Cellular Therapies (ITCI), CytomX Therapeutics (CTMX), Zai Lab (ZLAB), TG Therapeutics (TGTX) and Retrophin (RTRX).
Who are Rocket Pharmaceuticals' key executives?
Rocket Pharmaceuticals' management team includes the folowing people:
- Mr. Gaurav Shah M.D., Chief Exec. Officer
- Mr. Brian Batchelder, Head of Fin. and VP
- Ms. Kinnari Patel PharmD, MBA, Head of Regulatory, Pharmacovigilance & Compliance and VP
- Mr. Jonathan Schwartz M.D., Chief Medical Officer and Head of Clinical Devel.
- Mr. Naveen Yalamanchi, Chief Bus. Officer
Has Rocket Pharmaceuticals been receiving favorable news coverage?
Media headlines about RCKT stock have been trending somewhat positive on Friday, according to Accern. Accern scores the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Rocket Pharmaceuticals earned a daily sentiment score of 0.09 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 47.00 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
How do I buy shares of Rocket Pharmaceuticals?
Shares of RCKT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Rocket Pharmaceuticals' stock price today?
One share of RCKT stock can currently be purchased for approximately $17.10.
How big of a company is Rocket Pharmaceuticals?
Rocket Pharmaceuticals has a market capitalization of $685.78 million. Rocket Pharmaceuticals employs 20 workers across the globe.
How can I contact Rocket Pharmaceuticals?
Rocket Pharmaceuticals' mailing address is 430 EAST 29TH STREET SUITE 1040, NEW YORK NY, 10016. The biotechnology company can be reached via phone at 646-440-9100 or via email at [email protected]
MarketBeat Community Rating for Rocket Pharmaceuticals (RCKT)
MarketBeat's community ratings are surveys of what our community members think about Rocket Pharmaceuticals and other stocks. Vote "Outperform" if you believe RCKT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCKT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Rocket Pharmaceuticals in the last 12 months. Their average twelve-month price target is $10.6667, suggesting that the stock has a possible downside of 37.62%. The high price target for RCKT is $27.00 and the low price target for RCKT is $2.00. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Hold | Hold |
| Consensus Rating Score: | 2.50 | 2.50 | 2.00 | 2.25 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $10.6667 | $10.6667 | $2.50 | $4.50 |
| Price Target Upside: | 37.62% downside | 40.64% downside | 163.16% upside | 373.68% upside |
Rocket Pharmaceuticals (NASDAQ:RCKT) Consensus Price Target History
Rocket Pharmaceuticals (NASDAQ:RCKT) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
Rocket Pharmaceuticals (NASDAQ:RCKT) Earnings History and Estimates Chart
Rocket Pharmaceuticals (NASDAQ RCKT) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/9/2018 | | | | | | | | |
| 8/3/2017 | Q2 2017 | ($0.47) | ($0.24) | | | View | N/A |  |
| 5/10/2017 | Q1 2017 | ($0.3930) | ($0.40) | | | View | N/A | |
| 3/16/2017 | Q4 2016 | ($0.4320) | ($0.4810) | | | View | N/A | |
| 11/9/2016 | Q3 2016 | ($0.45) | ($0.41) | | | View | N/A | |
| 8/10/2016 | Q2 | ($0.40) | ($0.33) | | | View | N/A | |
| 5/11/2016 | Q1 | ($0.22) | ($0.38) | | | View | N/A | |
| 3/23/2016 | Q4 | ($0.37) | ($0.13) | | | View | N/A | |
| 11/12/2015 | Q3 2015 | ($1.84) | ($1.00) | | | View | N/A | |
| 8/6/2015 | Q2 2015 | ($0.29) | ($0.26) | | | View | N/A | |
| 5/15/2015 | Q1 2015 | | $0.80 | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Rocket Pharmaceuticals (NASDAQ:RCKT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Rocket Pharmaceuticals (NASDAQ RCKT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.30%
Rocket Pharmaceuticals (NASDAQ RCKT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/6/2017 | David P. Southwell | Insider | Buy | 60,000 | $1.75 | $105,000.00 | | |
| 5/13/2016 | J Martin Carroll | Director | Buy | 10,000 | $9.03 | $90,300.00 | 10,000 | |
| 2/23/2015 | Argeris N Karabelas | Director | Buy | 603,832 | $6.00 | $3,622,992.00 | | |
| 2/23/2015 | Park Bioventures Lp Devon | Major Shareholder | Buy | 814,166 | $6.00 | $4,884,996.00 | | |
(Data available from 1/1/2013 forward)
Rocket Pharmaceuticals (NASDAQ RCKT) News Headlines
| Source: |
|
Rocket Pharmaceuticals (NASDAQ:RCKT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Rocket Pharmaceuticals (NASDAQ:RCKT) Income Statement, Balance Sheet and Cash Flow Statement
Rocket Pharmaceuticals (NASDAQ RCKT) Stock Chart for Friday, April, 20, 2018
Loading chart…
